Lauren Strosnick

Lauren’s practice focuses on intellectual property litigation, with an emphasis on patent litigation. She handles cases spanning a broad range of technologies – from antibody therapeutics, pharmaceutical formulations, and medical devices to computer software, user interface design, and video surveillance systems. Lauren has experience with all phases of litigation, including pre-suit analysis, all aspects of discovery, taking and defending depositions, claim construction, expert reports, motions practice, oral argument, trial and appeals. Her practice includes Hatch-Waxman litigation, cases arising under the Biologics Price Competition and Innovation Act (BPCIA), and post-grant proceedings at the US Patent and Trademark Office (USPTO). Additionally, Lauren has handled cases involving allegations of trade secret misappropriation and breach of contract.

While in law school, Lauren received numerous Witkin and CALI Awards for academic excellence in various subject areas, including contracts and food and drug law. She also served as an editor for the Santa Clara High Technology Law Journal, externed for Technology Center 1600 (Biotechnology) at the USPTO in Washington, DC, and prosecuted patent applications in cloud computing.

Lauren’s representative cases include:

• Represented a biopharmaceutical company in Hatch-Waxman patent litigation, leading to the launch of client’s inhaled powder product for treating pulmonary arterial hypertension; also represented client in trade secret litigation concerning the same product.
• Represented an eyecare technology company in patent litigation where the team won a jury verdict of willful infringement, validity of client’s intraocular stent patents, and $34 million in damages.
• Represented a software company in patent litigation where the team invalidated all asserted patents involving location-based augmented reality; affirmed by the Federal Circuit.
• Represented a software company in patent litigation where the team invalidated all asserted claims involving multifunctional hotspot technology; affirmed by Federal Circuit.
• Represented home security company in patent litigation where the team invalidated all five asserted patents involving video surveillance systems; affirmed by the Federal Circuit.
• Represented an immunotherapy company in trade secret and breach of contract litigation involving T-cell engaging therapies in the Delaware Court of Chancery, where the team obtained a ruling of no misappropriation or breach, enabling the client to retain rights to its platform technology.
• Represented a biotechnology company in BPCIA patent litigation where the team defeated a temporary restraining order and preliminary injunction, enabling the client to launch its biosimilar product for treating HER2+ breast cancer and gastric cancer; affirmed by the Federal Circuit.
• Represented a biopharmaceutical company in patent litigation resulting in early case dismissal on statutory safe harbor grounds, enabling the client to continue developing its flagship product.

Publications and speaking engagements:

• Speaker and moderator, “Building a Career in IP and Emerging Technologies,” Law at the Edge: Trending Topics in Technology by the Institute for Law and Technology, June 2025
• Speaker, “Meeting of the Minds: Meet-and-Confer Strategies for IP Lawyers,” Mandatory Continuing Legal Education (MCLE), July 2023
• Speaker, “The BPCIA Turns 10 – Lessons Learned,” MCLE, October 2020
• Speaker, “IP Litigation Training Series: Overview of Responsive Pleadings,” MCLE, June 2020
• Co-author, “Roberts Was Wrong: Increased Antitrust Scrutiny After FTC v. Actavis Has Accelerated Generic Competition,” Virginia Journal of Law and Technology, Vol. 19, No. 3, 2015